Floatz logo

gsk1120212

Erdheim-Chester Disease

Cancer Research UKPhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Erdheim-Chester Disease cohort.

Asset / SponsorPhaseRating
Dabrafenib
Cancer Research UK
Phase 2/3B
Cobimetinib
Cancer Research UK
Phase 2/3B
VEMURAFENIB
Cancer Research UK
Phase 2/3CCC
hlx208
Shanghai Henlius Biotech
Phase 2CCC
hh2710
Haihe Biopharma Co., Ltd.
Phase 1/2CCC

View all 10 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant
BB
Indicative ·
69 / 100
View asset →
Glioma, High GradeDormant
BB
Indicative ·
69 / 100
View asset →
anaplastic oligodendrogliomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →